标题
Correlation of immune phenotype with IDH mutation in diffuse glioma
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume 19, Issue 11, Pages 1460-1468
出版商
Oxford University Press (OUP)
发表日期
2017-03-17
DOI
10.1093/neuonc/nox054
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
- (2016) Jung Ho Kim et al. BRITISH JOURNAL OF CANCER
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
- (2016) Pierre Bady et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
- (2016) Anna Sophie Berghoff et al. JOURNAL OF NEURO-ONCOLOGY
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- In search of a target: PD-1 and PD-L1 profiling across glioma types
- (2016) Anna S. Berghoff et al. NEURO-ONCOLOGY
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
- (2015) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
- (2015) Jaemoon Koh et al. MODERN PATHOLOGY
- Mutational landscape and clonal architecture in grade II and III gliomas
- (2015) Hiromichi Suzuki et al. NATURE GENETICS
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- (2015) Matthias Preusser et al. Nature Reviews Neurology
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma
- (2015) Sebastian Kurscheid et al. GENOME BIOLOGY
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
- (2015) K. M. Mahoney et al. Cancer Immunology Research
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
- (2015) D. A. Reardon et al. Cancer Immunology Research
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
- (2015) Anna S Berghoff et al. OncoImmunology
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
- (2014) Anna Sophie Berghoff et al. HISTOPATHOLOGY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
- (2013) Anna Sophie Berghoff et al. CLINICAL NEUROPATHOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor
- (2011) Anna M Dahlin et al. MODERN PATHOLOGY
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2010) Lenny Dang et al. NATURE
- Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
- (2009) David Capper et al. BRAIN PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started